Dalteparin to prevent blood clots in people with severe traumatic brain injury
Tests dalteparin against saline for preventing blood clots in adults with traumatic brain injury.
Key facts
- Who runs it
- Sunnybrook Health Sciences Centre
- Where
- Canada12 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury (PROTEST)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 1,100 people, planned
- Started
- 19 Jul 2018
- Expected to end
- Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Dalteparin
- Saline
- Record updated
- 19 September 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a severe or moderate traumatic brain injury (head injury). It tests whether Dalteparin, a blood thinner, prevents blood clots compared with saline.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Severe TBI with a GCS (coma score) of ≤8. Or moderate TBI with GCS 9-12, in intensive care, with bleeding in the brain on the first CT scan. Moderate cases also need a breathing machine at screening, or more bleeding on a repeat CT scan.
- Earlier treatment
- The first dose of study drug must be possible within the first 3 calendar days after the injury.
Main reasons for not taking part
- Known allergy to FRAGMIN (Dalteparin), other heparins, benzyl alcohol or pork products
- Past heparin-induced low platelet count, or uncontrollable active bleeding or major clotting disorders
- Severe uncontrolled high blood pressure (BP>210 despite medications)
- Known pregnancy
- Weight under 45 kg (99 lb) or over 120kg (265 lb (120 kg)), or not expected to survive more than 48 hours from admission
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- The pragmatic nature of this study seeks to include all consecutive patients presenting with significant TBI, regardless of whether ICB is evident at presentation. Inclusion criteria are the following:
- Patients with severe TBI defined as GCS of ≤8, or
- Patients with moderate TBI defined as GCS = 9-12, admitted to ICU, with at least some ICB present on initial CT scan and any of the following:
- Requiring invasive mechanical ventilation at the time of screening
- Increased ICB on repeat CT scan compared to initial CT scan
- Upon randomization the patient will be able to receive the first dose of study drug in the first 3 calendar days from the time of injury
- ≥ 18 years of age
Who cannot take part
- Known Hypersensitivity to FRAGMIN (Dalteparin), or its constituents including benzyl alcohol or to other low molecular weight heparins and/or heparins or pork products
- Uncontrollable active bleeding
- Known major blood clotting disorders
- Known acute gastroduodenal ulcer (with active bleeding)
- Severe uncontrolled hypertension (i.e. BP>210 despite medications)
- Presence of another confounding factor that can adequately explain the poor GCS at time of presentation (e.g. drug toxicity, seizure)
- Known history of confirmed or suspected immunologically-mediated heparin-induced thrombocytopenia (delayed-onset severe thrombocytopenia), and/or in patients with a known history of a positive in vitro platelet-aggregation test in the presence of FRAGMIN (Dalteparin) is positive
- All participants meeting any of the following exclusion criteria at baseline will be excluded from participation in this study:
- Known septic endocarditis
- Known diabetic or hemorrhagic retinopathy
- Anticipated to be unable to receive SCD on at least one lower extremity due to nature of injuries for duration of intervention period
- Known presence of irreversible coagulopathies
- Known Pregnancy
- Participants extremely low weight (<45 kg), or extremely high weight (>120kg)
- Not expected to survive more than 48 hours from admission
This trial is currently available in Canada.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a phase III, multi-centre, double blind, randomized controlled trial of patients with traumatic brain injury (TBI).
The 2 groups in the trial
- AnticoagulantExisting treatment, for comparison
Dalteparin sodium (at a dose of 5000 IU once daily by subcutaneous injection) for 7 days upon randomization after hospital admission.
Treatment: Dalteparin
- SalinePlacebo, for comparison
Saline (0.2 mL) once daily by subcutaneous injection for 7 days upon randomization after hospital admission.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- PROTEST Trial - PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury, a Double-blind Randomized Controlled Trial
- Plain-language title
- Dalteparin to prevent blood clots in people with severe traumatic brain injuryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Publications
- Record updated
- 19 September 2024